New-generation recombinant factor concentrates: bridge to gene therapy (Q34176033)

31 July 2017

1 reference

title

New-generation recombinant factor concentrates: bridge to gene therapy (English)

1 reference

31 July 2017

0 references

Ragni MV

1 reference

31 July 2017

publication date

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

7 Suppl 1

1 reference

31 July 2017

page(s)

28-35

1 reference

Hemophilia in the Talmud and Rabbinic Writings

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

A concentrate of human antihaemophilic factor; its use in six cases of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood‐borne virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Can we improve on nature? "Super molecules" of factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

The natural history of the immune response to exogenous factor VIII in severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Structure of the C2 domain of human factor VIII at 1.5 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Antibody response to a T-dependent antigen requires B cell expression of complement receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00097.X

10.1046/J.1365-2516.2001.00097.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference